Isabelle Mahé: Reduced-Dose Apixaban Lowers Bleeding Risk in CAT Without Losing Efficacy
Isabelle Mahé, Head of Internal Medicine at the Louis Mourier Hospital, APHP at Paris Cité University, shared a post on LinkedIn about several recent articles she and her colleagues co-authored, adding:
”In patients with CAT receiving extended treatment, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding․
4 clinical predictors were significantly associated with increased CRB risk:
- anaemia and/or
- thrombocytopenia,
- age ≥75, PE as the index event,
- male sex (The Lancet Haematology)․
The accumulation of bleeding risk predictors emerged as a major determinant of clinically relevant bleeding, with consistent patterns across dosing regimens. (The Lancet Haematology)․
In patients with bleeding risk predictors, a lower clinically relevant bleeding with reduced-dose apixaban was observed.
Those data reinforce the clinical relevance of the API-CAT findings, including for patients with non-modifiable bleeding risk factors․
Please read our reply just published in The Lancet Haematology!”
Title 1: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez
Read the Full Article on The New England Journal of Medicine․
Title 2: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti
Read the Full Article on The Lancet Haematology․
Title 3: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE – Authors’ reply
Authors: Isabelle Mahé, Céline Chapelle, Silvy Laporte
Read the Full Article on The Lancet Haematology․
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 21, 2026, 17:55Gayatri Kotwal։ New Review on Anemia, Pain, and Nutritional Deficiencies in Cancer Patients
-
Oct 21, 2026, 17:40Tetsuzan Ron: Iron Deficiency Without Anemia Clinical Impact and Management
-
Oct 21, 2026, 17:29Amir Hossien Esfandiari։ The Association Between Viral Infections and Aplastic Anemia
-
Oct 21, 2026, 17:16Melissa Hollo: A Meaningful Step Forward for Women’s Health
-
Oct 21, 2026, 17:09Chipili Ng’onga: Have You Ever Seen a Result That Just Didn’t Make Sense?
-
Oct 21, 2026, 16:57Fabrice Cognasse: Celebrating the Next Generation of Platelet Research and Transfusion Medicine
-
Oct 21, 2026, 16:47Christabel Odeta: Treating Pediatric Cancer in Children With Sickle Cell Disease
-
Oct 21, 2026, 16:36Sharlene Haywood: Bringing Multidisciplinary Learning Into Nursing Practice
-
Oct 21, 2026, 16:19Vanessa Carvalho: New Research on Platelet-Derived Extracellular Vesicles in Preeclampsia